Alliance for Pharmacy Compounding

Though Alliance for Pharmacy Compounding has engaged thousands of patients and compounders in our campaign to preserve compounded hormone therapy, prescribers continue to be largely absent. It’s up to you to educate them about the threat, and we’ve developed a new resource to help you do that.

Download and ask your sales reps to share it—either a hard copy or the digital version—with all the prescribers of compounded hormones you work with. What they don’t know about FDA’s implicit threat to restrict cBHT can hurt them and their patients. Help us engage them.

Another NASEM Conflict of Interest

A recent article revealed that the National Academies of Science, Engineering and Medicine reportedly received funds—to the tune of $19 million—from members of the Sackler family, a few of whom are associated with the family business, Purdue Pharma.

Hmmm. Sounds familiar, a lot like FDA’s inappropriate influencing of NASEM’s 2020 report on compounded hormones.

According to the article, some efforts have been made over the years to discredit the NASEM reports that were funded by members of the OxyContin manufacturer, but these attempts are too little, too late. One of the scientists interviewed for the article remarked that “the group’s longtime failure to disclose financial ties between committee members and industry placed the Academies in the ‘dark ages’ of research integrity.” 

Exactly.